Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, announced that CEO Sean P. Bohen will participate in a virtual fireside chat at the Jefferies 2021 Virtual Healthcare Conference on June 1, 2021, at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, announced that CEO Sean P. Bohen will participate in a virtual fireside chat at the Jefferies 2021 Virtual Healthcare Conference on June 1, 2021, at 4:30 p.m. ET. The webcast will be available on Olema's website and archived for 14 days. Olema's lead candidate, OP-1250, is currently in a Phase 1/2 trial for ER-positive, HER2-negative breast cancer.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was -0.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 p.m. ET (1:30 p.m. PT).
A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com
617-721-8194
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.